BrightGene Bio Medical Technology C - Asset Resilience Ratio

Latest as of March 2024: 1.00%

BrightGene Bio Medical Technology C (688166) has an Asset Resilience Ratio of 1.00% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is BrightGene Bio Medical Technology C's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥51.01 Million

≈ $7.46 Million USD Cash + Short-term Investments

Total Assets

CN¥5.09 Billion

≈ $744.46 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2023)

This chart shows how BrightGene Bio Medical Technology C's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 688166 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down BrightGene Bio Medical Technology C's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 688166 total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥51.01 Million	1.0%
Total Liquid Assets	CN¥51.01 Million	1.00%

Asset Resilience Insights

Limited Liquidity: BrightGene Bio Medical Technology C maintains only 1.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

BrightGene Bio Medical Technology C Industry Peers by Asset Resilience Ratio

Compare BrightGene Bio Medical Technology C's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for BrightGene Bio Medical Technology C (2016–2023)

The table below shows the annual Asset Resilience Ratio data for BrightGene Bio Medical Technology C.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	1.01%	CN¥50.62 Million ≈ $7.41 Million	CN¥5.03 Billion ≈ $736.32 Million	-0.07pp
2022-12-31	1.08%	CN¥50.12 Million ≈ $7.33 Million	CN¥4.66 Billion ≈ $682.09 Million	+1.05pp
2021-12-31	0.03%	CN¥763.45K ≈ $111.72K	CN¥2.97 Billion ≈ $434.55 Million	-9.82pp
2020-12-31	9.85%	CN¥180.04 Million ≈ $26.35 Million	CN¥1.83 Billion ≈ $267.46 Million	+9.53pp
2016-12-31	0.32%	CN¥1.21 Million ≈ $177.54K	CN¥384.19 Million ≈ $56.22 Million	--

pp = percentage points

About BrightGene Bio Medical Technology C

SHG:688166 China Biotechnology

Market Cap

$2.28 Billion

CN¥15.57 Billion CNY

Market Cap Rank

#5780 Global

#1096 in China

Share Price

CN¥36.81

Change (1 day)

+1.52%

52-Week Range

CN¥29.53 - CN¥72.50

All Time High

CN¥116.49